NCT07361640Recruiting
DiaMester Pilot RCT: E-health Lifestyle Program for Type 2 Diabetes
DiaMester: E-health Lifestyle Program for Improved Self-management and Remission of Type 2 Diabetes - a Pilot RCT
Source: ClinicalTrials.gov · Last updated 23 Jan 2026
Brief summary (registry, in English)
This registration covers a pilot for a 3-armed parallel-group randomized controlled trial (RCT) that will evaluate the efficacy of DiaMester, a Norwegian e-health programme designed to improve self-management and induce clinically meaningful weight loss, and thereby potential remission in adults with type 2 diabetes (T2D).
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 99 (estimated)
- First submitted
- 15 Jan 2026
- Start date
- 14 Jan 2026
- Primary completion date
- 30 Sept 2027
- Lead sponsor
- Oslo University Hospital
- Diseases
- Type 2 diabetes
- NCT number
- NCT07361640
What you commit to
- Study type: Interventional
- Planned participants: 99
- From 14 Jan 2026 to the primary completion date, 30 Sept 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- \> 5% weight change or started treatment with weight reducing drugs\* within the last 6 months. \*orlistat (Xenical), bupropion-naltrekson (Mysimba), fenteramin-topiramat (Qsimba), semaglutid (Wegovy, Ozempic), tirzepatid (Mounjaro), liraglutid (Saxenda, Victoza), dulaglutid (Truicity).
- Myocardial infarction within previous 6 months
- Substance abuse (drugs, alcohol)
- Patients who have required hospitalization for depression or are on antipsychotic drugs
Other illness
- Known cancer
- Severe heart failure defined as equivalent to the New York Heart Association grade 3 (NYHA)
- Diagnosed eating disorders or suspected ED based on screening questionnaire
Lab values
- Recent routine HbA1c ≥108 mmol/mol
- Recent eGFR \<30 ml/min/1.73 m\^2
Other
- Current insulin use
- Pregnancy/considering pregnancy or exclusively breastfeeding
- Learning difficulties or unable to understand, speak and read Norwegian or English
- People currently participating in another clinical research trial
Who the study is looking for
- Written informed consent
- Men and women aged ≥ 18 years
- Type 2 diabetes of duration 0-6 years (diagnosis based on 2 recorded diagnostic-level tests, HbA1c and/or blood glucose)
- HbA1c ≥ 48 mmol/mol at the last routine clinical check, within last 12 months if on diet alone
- HbA1c ≥ 43 mmol/mol if on treatment with oral hypoglycaemic agents or GLP-1 RA treatment
- Body Mass Index (BMI) \>27 kg/m2
- Stable body weight during the last 6 months with or without the use of weight-reducing drugs
- Self-reported desire to lose weight
- Owns a smartphone
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Oslo University Hospital Coordinator of this site? Confirm its status | Oslo | Norway | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.